

REMARKS/ARGUMENTS

Amendments to the specification.

Support for the present amendment to amend the Sequence Listing can be found in the Sequence Listing as filed, and in the specification which provides the text used in the <223> lines of the Substitute Sequence Listing.

This Substitute Sequence Listing recorded in computer readable form is identical to the Sequence Listing as filed with this patent application except for the sequences added by previous amendment, said sequences being supported by their description in the specification, the deletion of redundant "<223> Artificial sequence" comment lines, and the present additions of <223> lines derived directly from the sequence descriptions in the specification.

This Substitute Sequence Listing thus contains no new matter.

Applicants believe that no additional fee is due with this communication. However, if the USPTO determines that a fee is due, the Commissioner is hereby authorized to charge Mendel Biotechnology, Inc. Deposit Account No. 50-1025.

Respectfully submitted,
MENDEL BIOTECHNOLOGY, INC.



Date: 12 March 2008

Jeffrey M. Libby, Ph.D.
Reg. No. 48,251

3935 Point Eden Way
Hayward, California 94545
Phone: (510) 259-6138
Fax: (510) 264-0259

JML/jml